These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22378262)

  • 1. Tafamidis.
    Said G; Grippon S; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Mar; 11(3):185-6. PubMed ID: 22378262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
    Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 8. Tafamidis: a review of its use in familial amyloid polyneuropathy.
    Scott LJ
    Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In brief: Tafamidis (Vyndaqel; Vyndamax) for transthyretin amyloid cardiomyopathy.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):16. PubMed ID: 31999671
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
    Lockwood PA; Le VH; O'Gorman MT; Patterson TA; Sultan MB; Tankisheva E; Wang Q; Riley S
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):849-854. PubMed ID: 32196976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
    N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
    Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
    Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 20. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.